PHARMACEUTICAL 2023

Biofrontera Inc
Rank 243 of 471



PHARMACEUTICAL 2023

Biofrontera Inc
Rank 243 of 471

The relative strengths and weaknesses of Biofrontera Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Biofrontera Inc compared to the market average is the variable Comprehensive Net Income, increasing the Economic Capital Ratio by 83% points.The greatest weakness of Biofrontera Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 82% points.

The company's Economic Capital Ratio, given in the ranking table, is 255%, being 9.9% points above the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	43,140
Cost of Goods Sold	0
Intangible Assets	3,032
Liabilities, Current	20,894
Liabilities, Non-Current	869
Other Assets	4,508
Other Compr. Net Income	0
Other Expenses	12,150
Other Liabilities	5,243
Other Net Income	17,973
Other Revenues	28,674
Property and Equipment	204
Research and Development	0
Selling, General and Administrative Expense	35,137

Output Variable	Value in 1000 USD
Assets	50,884
Liabilities	27,006
Expenses	47,287
Revenues	28,674
Stockholders Equity	23,878
Net Income	-640
Comprehensive Net Income	-640
BaseVar	85,912
ECR before LimitedLiability	132%
Economic Capital Ratio	255%